Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks

By afschroeder • May 10, 2026

Sofen HL, Gogineni R, Nishandar T, Bagel J. Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks. Dermatol Ther (Heidelb). 2026 May 9. doi: 10.1007/s13555-026-01774-2. Epub ahead of print. PMID: 42105056.

Tags: Dermatology, Investigator Global Assessment modified 2011 of the scalp (IGA mod 2011 [scalp]) score, Obesity, Olive View DoM, plaque psoriasis, Psoriasis Scalp Severity Index (PSSI), Publications, scalp psoriasis, tildrakizumab

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A. Early and Maintained[...]

Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline

Smart K, Armstrong AW, Adler BL. Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline. Dermatitis. 2026 Sep[...]